MedTrace Logo

MEtatastic Renal Carcinoma LINes

NCT03928964 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 440

Last updated 2019-04-30

No results posted yet for this study

Summary

The hypothesis of this study are as follows:

* Prognostic evaluation of patients based on an integrative model provides better assessment of overall survival, and thus improves setting of care goals.
* In a routine care population, antitumour drugs may have a significant impact on overall survival through their targeted antitumor effect, but also through their toxicity profile and their impact on comorbidities.
* The optimization of patient support (supportive care, drug tolerance monitoring) can have an impact on the prognosis.

Conditions

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Principal Investigators

  • Benoit Rousseau, MD · Henri Mondor University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-15
Primary Completion
2018-10-03
Completion
2019-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03928964 on ClinicalTrials.gov